TERROSA teriparatide 0.25 mg/mL (250mcg/mL) solution for injection cartridge and pen (Switzerland)

TERROSA is indicated for:

• the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures.
• the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.